Aurobindo Pharma says Rs 420 cr deal to acquire 51% in Cronus Pharma cancelled

Aurobindo Pharma says Rs 420 cr deal to acquire 51% in Cronus Pharma cancelled

PTIUpdated: Friday, August 20, 2021, 11:42 PM IST
article-image
On August 12, Aurobindo Pharma had announced that it had entered into definitive agreements to subscribe to fresh equity shares in Hyderabad-based Cronus, a generic veterinary pharmaceutical products firm/ Representational image |

Aurobindo Pharma Ltd on Friday said its Rs 420-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus) has been cancelled.

On August 12, the company had announced that it had entered into definitive agreements to subscribe to fresh equity shares in Hyderabad-based Cronus, a generic veterinary pharmaceutical products firm engaged in development, manufacturing and sale of these items.

The company had entered into binding agreements with Cronus for acquisition of 51 per cent ownership by subscribing to 95,059,963 equity shares of Rs 10 each at a premium of Rs 34.18 per equity share aggregating to Rs 420 crore.

In a regulatory filing on Friday, Aurobindo Pharma said, "The board of directors in its meeting held today has approved the termination of the aforesaid agreements, and the parties have mutually agreed and terminated the said agreements." It, however, did not disclose the reasons for the termination of the proposed deal.

At the time of the announcement of the deal, Aurobindo Pharma had said the acquisition would provide it a foothold in the $48 billion global animal health market. Cronus has 67 products in its pipeline, of which 22 have been filed and six have been approved by the Centre for Veterinary Medicine, USFDA.

RECENT STORIES

HCL Tech Q1 FY26 Results: Net Profit Falls 10% To ₹3,843 Crore, Revenue Up 8% YoY; Declares ₹12...

HCL Tech Q1 FY26 Results: Net Profit Falls 10% To ₹3,843 Crore, Revenue Up 8% YoY; Declares ₹12...

Income Tax Dept Raids 150 Locations Across Country Against Fraudulent Tax Benefits And Fake TDS...

Income Tax Dept Raids 150 Locations Across Country Against Fraudulent Tax Benefits And Fake TDS...

Income Tax Dept Launches Nationwide Crackdown On Fake ITR Deductions; ₹1,045 Crore In False Claims...

Income Tax Dept Launches Nationwide Crackdown On Fake ITR Deductions; ₹1,045 Crore In False Claims...

InGovern Flags Regulatory Loopholes As Viceroy Report On Vedanta Sparks Concern Over Unregulated...

InGovern Flags Regulatory Loopholes As Viceroy Report On Vedanta Sparks Concern Over Unregulated...

Kesoram Industries’ Q1 Loss Widens To ₹99.3 Crore, Revenue Drops 9.3% YoY

Kesoram Industries’ Q1 Loss Widens To ₹99.3 Crore, Revenue Drops 9.3% YoY